Arbutus Biotech (ABUS) heads to a key March Moderna LNP patent trial as imdusiran HBV milestones drive value—get the latest ...

Protagonist (PTGX) is a high-conviction buy: late-stage icotrokinra & rusfertide near 2026 milestones, strong cash runway. Read more here.

Based on key financial metrics such as the price-to-sales ratio, shareholder yield and the price-earnings ratio, the ...

February 2026 Update on US regulatory review of Saphnelo subcutaneous administration in systemic lupus erythematosus The US Food and Drug Administration (FDA) issued a complete response letter (CRL) ...

When our body fights an infection, the immune system must quickly activate defenses and trigger a beneficial inflammatory ...

Small-molecule mitochondrial transcription factor A modulators stabilize mtDNA, preventing cytosolic escape and suppressing cGAS-STING interferon signaling, while improving bioenergetics and fibrosis ...

Potential expansion of the BESREMi® (ropeginterferon alfa-2b-njft) product label to include adult patients with essential thrombocythemia (ET) BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA ...

PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles ...

EXCEED-ET Study Results Demonstrate Significant Efficacy, with Consistent Treatment Response Across the Overall Essential Thrombocythemia Population Results Extend Previously Reported Positive Phase 3 ...

ropeginterferon alfa-2b-njft recognized by National Comprehensive Cancer Network® (NCCN®) as recommended treatment option, listing it as a Category 1 preferred regimen for ET patients with inadequate ...

Prolia (denosumab) can cause side effects that range from mild to serious. Examples include joint pain and tooth and jaw-related side effects. If side effects from Prolia become difficult to tolerate, ...